English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of this study was to evaluate the impact of routinely administered treatment with indacaterol and/or glycopyrronium on quality of life and level of dyspnoea of patients with chronic obstructive pulmonary disease (COPD) in a real-life setting. Material and methods: It was an observational, non-interventional study in patients with stable, symptomatic chronic obstructive pulmonary disease initiating treatment with indacaterol and/or glycopyrronium as part of routine care. The primary outcomes included a change in quality of life measured using the Clinical COPD Questionnaire (CCQ) and level of dyspnoea evaluated using the modified Medical Research Council scale (mMRC). Patients were followed up for 6 months after initiation of treatment. Results: Analysis included baseline data from 586 patients. At 6 months 82.5% (n = 483) of patients were continuing initiated treatment. Improvement of mMRC and CCQ scores was observed in all treatment arms. The mean total CCQ score ± SD changed after 6 months from 2.2 ±0.9 to 1.2 ±0.9 in the indacaterol group (p < 0.001), from 2.1 ±1.0 to 1.0 ±0.9 (p < 0.001) in the glycopyrronium group and 2.6 ±1.1 at baseline to 1.3 ±1.0 (p < 0.001) in the indacaterol/glycopyrronium group. The mean mMRC ± SD decreased from 2.1 ±0.9 to 1.4 ±0.9 (p < 0.001) in the indacaterol group, from 2.1 ±0.9 to 1.2 ±1.0 (p < 0.001) in the glycopyrronium group, and from 2.3 ±0.8 to 1.4 ±0.9 (p < 0.001) in the indacaterol/glycopyrronium group. Conclusions: Use of indacaterol and/or glycopyrronium improved quality of life and breathlessness in patients with stable COPD, efficiently reducing the symptoms burden.

archives of medical sciences. civilization diseases

Quality of life of patients with chronic obstructive pulmonary disease treated with indacaterol and/or glycopyrronium: a real-world Polish observational study